Global Human Insulin Market By Overview
Human Insulin Market accounted for USD 22.97 Billion in 2020 and is estimated to be USD 35.01 Billion by 2030 and is anticipated to register a CAGR of 4.3%.
Insulin regulates fat and carbohydrate metabolism in the body. It is a peptide hormone, which is secreted in the pancreas by beta cells of the islets of Langerhans and it helps to regulate the glucose metabolism. It causes skeletal muscle cells and fat tissues to absorb glucose from the blood. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.
Global Human Insulin Market By Drivers & Restraints
Rising prevalence of diabetes
The growth of global human insulin market is primarily attributed to rising prevalence of diabetes. The factors that contribute to growing number of diabetic patient globally include changes in lifestyles, growing number of obese as well as geriatric population and inadequate healthcare services. Favorable government policies and technological advances such as innovation of insulin pens have also fueled the growth of this market. Pipeline insulin products and untapped emerging economies are the promising opportunities for the manufacturers of global human insulin. With the growing need for human insulin this market consist various opportunities such as application of regulations against needle anxiety, needle stick injuries, and rising awareness related to the danger of blood borne pathogen transmission. Additionally, increasing demand for biosimilar drugs because they are cost effective that are considered as the growth drivers for the global human insulin market. However, limited access to human insulin in emerging economies and uneven pricing may affect the target market growth.
Moreover, cost of production, manufacturing complexities and critical regulatory requirements for the approval of biotechnology derived products are the factors that could hinder the growth of global human insulin market. Nevertheless, with growing effort for in healthcare sector by government and various organization may help in overcoming these limitations.
Global Human Insulin Market By Segmentations & Regional Insights
The global human insulin market is segmented based on product type, and region.
Based on product type, the global human insulin market is segmented into first-basal or long-acting insulins which is further segmented on the basis of brands Lantus, Levemir, Toujeo, Tresiba, and Basagla, second-bolus or fast-acting insulins which is categorized on the basis of brands NovoRapid/Novolog, Humalog, Apidra, FIASP, and Admelog, third-traditional human insulins is divided into Novolin/Actrapid/Insulatard, Humulin, and Insuman, fourth-combination insulins is separated into NovoMix, Ryzodeg, Xultophy, and Soliqua/Suliqua, and fifth-biosimilar insulins Insulin Glargine Biosimilars, and Human Insulin Biosimilars. Biosimilar drugs were likely to add up for the biggest market share of the global human insulin market and are expected to stay the same in the near future. Long acting modern insulin and premixed modern insulin are the fastest growing categories of this segment. Amongst traditional and modern brands, Lantus holds the largest market share, whereas, Levemir and Apidra are the fastest growing insulin drugs.
Regional Insights:
Based on the region the global human insulin market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America accounts highest revenue share to the global human insulin market due to growing demand for advanced medical technologies and increasing geriatric population. Asia Pacific human insulin market is projected to register a high CAGR over the forecast period owing to the growing trend of high prevalence of diabetes and technological advances in effective insulin delivery.
Attribute |
Details |
Base year for estimation |
2020 |
Forecast period |
2020 – 2029 |
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
Market Segmentation |
By Product Type- Basal or Long-Acting, Bolus or fast-Acting, Traditional Human Insulin, Combination Insulin and Biosimilar Insulin |
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Detailed Segmentation:
Global Human Insulin Market, By Product Type:
- Basal or Long-acting Insulins
- Lantus
- Levemir
- Toujeo
- Tresiba
- Basagla
- Bolus or Fast-acting Insulins
- NovoRapid/Novolog
- Humalog
- Apidra
- FIASP
- Admelog
- Traditional Human Insulins
- Novolin/Actrapid/Insulatard
- Humulin
- Insuman
- Combination Insulins
- NovoMix
- Ryzodeg
- Xultophy
- Soliqua/Suliqua
- Biosimilar Insulins
- Insulin Glargine Biosimilars,
- Human Insulin Biosimilars
Global Human Insulin Market, By Region:
- North America
- Middle East & Africa
- Middle East & Africa Human Insulin Market, By Product Type
- Middle East & Africa Human Insulin Market, By Country
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Latin America Human Insulin Market, By Product Type
- Latin America Human Insulin Market, By Country
- Brazil
- Mexico
- Rest of Latin America
- Asia Pacific
- Asia Pacific Human Insulin Market, By Product Type
- Asia Pacific Human Insulin Market, By Country
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Europe
- Europe Human Insulin Market, By Product Type
- Europe Human Insulin Market, By Country
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- North America Human Insulin Market, By Product Type
- North America Human Insulin Market, By Country
- U.S.
- Canada
- Middle East & Africa
Global Human Insulin Market By Competitive Landscape & Key Players
Key Players:
The key players operating the global human insulin market involves Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt, and GalxoSmithCline. In June 2018, Humulin R U-500 of Eli Lilly and Company, which was utilized in insulin pumps, showed better A1C lowering in people with type 2 diabetes. This was deemed great when compared to multiple daily injections, thus boosting the expansion of global human insulin market. Novo Nordisk is developing a first once-weekly long-acting insulin (LAI287) which is currently in phase 2. The insulin is indicated for both type-1 and type-2 diabetes patients.
Global Human Insulin Market By Company Profile
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- Biocon
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Adocia
- Merck & Co., Inc.
- Pfizer, Inc.
- GlaxoSmithKline
Global Human Insulin Market By Highlights
FAQs
The global human insulin market is segmented based on product type, and region.
The growth of global human insulin market is primarily attributed to rising prevalence of diabetes. The factors that contribute to growing number of diabetic patient globally include changes in lifestyles, growing number of obese as well as geriatric population and inadequate healthcare services.
The market in North America accounts highest revenue share to the global human insulin market due to growing demand for advanced medical technologies and increasing geriatric population.
The key players operating the global human insulin market involves Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt, and GalxoSmithCline.